{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:29:12Z","timestamp":1788820152535,"version":"build-2803163510"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T cell engagers (TCEs) are a class of T cell\u2013redirecting therapeutics that enhance antitumor immunity by bringing T cells into close proximity with malignant cells. Following their success in hematologic malignancies, TCEs are now being increasingly investigated for the treatment of solid tumors. The recent approval of tarlatamab for small cell lung cancer (SCLC) offers renewed hope in this setting. Nevertheless, clinical efficacy in solid tumors remains limited by immunosuppressive tumor microenvironments (TME), on-target\/off-tumor toxicity, and intrinsic or acquired resistance to TCEs. This review summarizes recent advances in TCE development for solid tumors, including refinements in molecular design, biomarker-guided patient selection, and rational combination strategies aimed at overcoming resistance and improving therapeutic outcomes. We also discuss emerging next-generation approaches, such as engager platforms that redirect other immune effector cells. Collectively, these innovations underscore the potential of more precise and effective engager-based therapies for solid tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1774471","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:47:12Z","timestamp":1779256032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Fan","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy","volume":"6","author":"Fuc\u00e0","year":"2021","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.2c01437","article-title":"Modular chemical construction of IgG-like mono-and bispecific synthetic antibodies (SynAbs)","volume":"9","author":"Thoreau","year":"2023","journal-title":"ACS Cent Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102799","article-title":"Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies","volume":"78","author":"Arvedson","year":"2022","journal-title":"Curr Opin Biotechnol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2448","article-title":"T-cell-engaging therapy for solid tumors","volume":"27","author":"De Miguel","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166962","article-title":"Arming oncolytic viruses with bispecific T cell engagers: the evolution and current status","volume":"1870","author":"Wang","year":"2024","journal-title":"Biochim Et Biophys Acta (BBA)-Molecular Basis Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.538","article-title":"538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp","volume":"9","author":"Sacco","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S923","DOI":"10.1016\/j.annonc.2022.07.947","article-title":"821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma","volume":"33","author":"Schlaak","year":"2022","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102076","article-title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","volume":"6","author":"Sacco","year":"2025","journal-title":"Cell Rep Med"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-81354-2_27","article-title":"Uveal melanoma: adjuvant and neoadjuvant therapy","volume-title":"Clinical Ophthalmic Oncology","author":"Khan","year":"2025"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-230","article-title":"Taking it up a notch: a promising immunotherapy against small cell lung cancer","volume":"12","author":"Apaydin","year":"2023","journal-title":"Trans Lung Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol And Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3361","article-title":"Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology","volume":"116","author":"Elmeliegy","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S784","DOI":"10.1016\/j.annonc.2022.07.651","article-title":"523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): phase I dose-escalation analysis","volume":"33","author":"Van Nieuwenhuysen","year":"2022","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5632","article-title":"A phase 1\/2 study of ubamatamab (REGN4018), a MUC16\u00d7CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer","volume":"42","author":"Van Nieuwenhuysen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S928","DOI":"10.1016\/j.annonc.2020.08.2002","article-title":"1496TiP phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"31","author":"Lordick","year":"2020","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.1073","article-title":"1073 AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens","volume":"12","author":"Natoli","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2519","article-title":"Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"42","author":"Zheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","article-title":"ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models","volume":"83","author":"Nakazawa","year":"2023","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2599","article-title":"A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors","volume":"36","author":"Ogita","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S622","DOI":"10.1016\/j.annonc.2023.09.2185","article-title":"1046P phase I\/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: preliminary dose escalation results","volume":"34","author":"Hong","year":"2023","journal-title":"Ann Oncol"},{"key":"B42","article-title":"Janux announces encouraging safety and efficacy data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in solid tumors","volume-title":"Business wire","year":"2024"},{"key":"B43","article-title":"CytomX Therapeutics announces positive initial phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 PROBODY\u00ae T-cell engager)","volume-title":"Business wire","year":"2024"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391954","article-title":"The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas","volume":"15","author":"Holzmayer","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0667","article-title":"667 A phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC)","volume":"10","author":"Pal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114666","article-title":"144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting T-cell engaging bispecific antibody for treatment of mesothelin-positive cancers","volume":"211","author":"Smans","year":"2024","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S875","DOI":"10.1016\/j.annonc.2022.07.854","article-title":"728O results from phase I dose escalation of IMC-F106C, the first PRAME\u00d7CD3 ImmTAC bispecific protein in solid tumors","volume":"33","author":"Hamid","year":"2022","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.887","article-title":"887 Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade","volume":"9","author":"Smith","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1\u00d7CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4649","article-title":"Trial in progress: a phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G\/GEJ) cancer","volume":"38","author":"Chao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS652","article-title":"A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors","volume":"43","author":"Levitz","year":"2025","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1200\/jco.2010.28.15_suppl.2573","article-title":"Phase I safety and pharmacology study of the EpCAM\/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer","volume":"28","author":"Fiedler","year":"2010","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT204","article-title":"Abstract CT204: phase 1a\/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)","volume":"85","author":"Modi","year":"2025","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.279","article-title":"Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC)","volume":"40","author":"Lim","year":"2022","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.07.009","article-title":"The extracellular matrix in solid tumor immunotherapy","volume":"45","author":"Cho","year":"2024","journal-title":"Trends Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.03.001","article-title":"Targeting CAFs to overcome anticancer therapeutic resistance","volume":"8","author":"Saw","year":"2022","journal-title":"Trends Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/nejmra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the step stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-812630-1.00007-4","article-title":"Tumor-associated antigens","volume-title":"Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation","author":"Alatrash","year":"2019"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102340","article-title":"Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours","volume":"104","author":"Crucitta","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1021\/nl403266t","article-title":"T cell activation is determined by the number of presented antigens","volume":"13","author":"Deeg","year":"2013","journal-title":"Nano Lett"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583044","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04175-8","article-title":"Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma","volume":"32","author":"Lee","year":"2026","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0236-7","article-title":"Tumour heterogeneity and metastasis at single-cell resolution","volume":"20","author":"Lawson","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2024.25.12.4457","article-title":"Deciphering antigen processing machinery (APM) as one of the determinants for responsiveness of affected patients towards anticancer immunotherapy","volume":"25","author":"Nurlaila","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/1538-7445.AM2017-55","article-title":"Generation of half-life extended anti-CD33 BiTE antibody constructs compatible with once-weekly dosing","volume":"77","author":"Arvedson","year":"2017","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669496","article-title":"Design of a trispecific checkpoint inhibitor and natural killer cell engager based on a 2 + 1 common light chain antibody architecture","volume":"12","author":"Bogen","year":"2021","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-022-02474-3","article-title":"Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo","volume":"41","author":"Passariello","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0061","article-title":"TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors","volume":"20","author":"Austin","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.121","article-title":"Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)","volume":"42","author":"Beltran","year":"2024","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1538-7445.AM2023-5121","article-title":"TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors","volume":"83","author":"Newhook","year":"2023","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1158\/1538-7445.AM2024-6716","article-title":"DLL3 TriTCE Co-Stim: a next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers","volume":"84","author":"Repenning","year":"2024","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/blood-2024-204614","article-title":"First-in-human phase 1 study of SAR442257 in patients with relapsed\/refractory multiple myeloma and non-Hodgkin lymphoma","volume":"144","author":"Schjesvold","year":"2024","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104199","article-title":"40O phase I\/Ib open-label study of an HER2-targeted T cell engager (TCE)\u2013SAR443216 in patients (pts) with advanced solid tumors: intravenous (IV) dose-escalation results","volume":"10","author":"Calvo","year":"2025","journal-title":"ESMO Open"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1158\/1538-7445.AM2023-2982","article-title":"TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors","volume":"83","author":"Poffenberger","year":"2023","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1538-7445.AM2023-2928","article-title":"TROP2 ProTriTAC, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors","volume":"83","author":"Rocha","year":"2023","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/jitc-2022-SITC2022.1325","article-title":"Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T cell engager for treatment of metastatic castration-resistant prostate cancer","volume":"10","author":"Diraimondo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"A908","DOI":"10.1136\/jitc-2021-SITC2021.867","article-title":"867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation","volume":"9","author":"Kwant","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1158\/1538-7445.AM2024-6343","article-title":"AnTenGagerTM, a novel \"2+1\" T cell engager platform, enables conditional T cell activation with reduced risk of CRS","volume":"84","author":"Hou","year":"2024","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"MAbs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1182\/blood-2023-181395","article-title":"Lbl-034, a highly differentiated T-cell engaging bispecific antibody targeting GPRC5D for the treatment of relapsed or refractory multiple myeloma","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e19584","article-title":"Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"40","author":"Giri","year":"2022","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7064","article-title":"A phase I\/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504","volume":"37","author":"Schwartz","year":"2019","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3002","article-title":"Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Tabernero","year":"2017","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"v122","DOI":"10.1093\/annonc\/mdx367.002","article-title":"Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab","volume":"28","author":"Sandoval","year":"2017","journal-title":"Ann Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9526","article-title":"Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma","volume":"39","author":"Orloff","year":"2021","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5632","article-title":"A phase 1\/2 study of ubamatamab (REGN4018), a MUC16\u00d7CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer","volume":"42","author":"Van Nieuwenhuysen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14587","article-title":"Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Falchook","year":"2024","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111012","article-title":"Anti-PD-L1 \u00d7 anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1","volume":"124","author":"Luangwattananun","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1 \u00d7 CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J Control Release"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.02.522257","article-title":"HSV-1 oncolytic virus targeting CEACAM6-expressing tumors using a bispecific T-cell engager","author":"Murad","year":"2023","journal-title":"bioRxiv"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2219544","article-title":"Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma","volume":"12","author":"Yuan","year":"2023","journal-title":"Oncoimmunology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343378","article-title":"Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy","volume":"15","author":"Zarezadeh Mehrabadi","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-023465","article-title":"Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-a\/\u00df on antigen cross-presentation","volume":"109","author":"Longman","year":"2007","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2651","article-title":"Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors","volume":"24","author":"Speck","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e34","article-title":"Current developments in NK cell engagers for cancer immunotherapy: Focus on CD16A and NKp46","volume":"24","author":"Shin","year":"2024","journal-title":"Immune Netw"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2026.2613561","article-title":"NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells","volume":"15","author":"Heger","year":"2026","journal-title":"Oncoimmunology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B132","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-020-00450-3","article-title":"A quantitative systems pharmacology model of T cell engager applied to solid tumor","volume":"22","author":"Ma","year":"2020","journal-title":"AAPS J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:47:14Z","timestamp":1779256034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":132,"alternative-id":["10.3389\/fimmu.2026.1774471"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774471","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1774471"}}